Roche seals two deals in one weekend

Share this article:

Roche closed two deals over one weekend: buying a drug from Spain's Oryzon Genomics and scooping up the Massachusetts company IQuum.

As reported by Bloomberg, the $21-million Oryzon deal is for an experimental drug that prevents cancers from growing and gives Roche “its first drug in human testing in the field of epigenetics,” a strategy in which doctors try to alter gene expression without DNA modification. The treatment is for acute myeloid leukemia. Bloomberg says Oryzon could garner an additional $500 million in milestone payments.

Roche's IQuum deal brings the private company's Laboratory-in-a-Tube system (known as Liat) into Roche's portfolio in exchange for $275 million, with a possible $175 million in additional payments. Roche said in a statement that IQuum will become part of Roche's Diagnostics division. The system “allows healthcare professionals to perform rapid molecular diagnostic testing in a point of care setting, closer to patients and with minimal training,” the company said.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions